Document is current

Article History

Received: 20 May 2022

Accepted: 4 February 2023

First Online: 24 February 2023

Declarations

:

: Alessio Cortellini received speaker fees and grant consultancies by AstraZeneca, MSD, BMS, Roche, Novartis and EISAI. Luca Cantini is granted by ESMO with an ESMO Translational Research Fellowship. Any views, opinions, findings, conclusions or recommendations expressed in this material are those solely of the author(s) and do not necessarily reflect those of ESMO. Melissa Bersanelli received research funding (Institutional) from Roche S.p.A., Pfizer, Seqirus UK, Novartis, Bristol Myers Squibb (BMS), AstraZeneca, Sanofi Genzyme; honoraria as a speaker at scientific events and for advisory role (personal fees) from BMS, MSD, Novartis, AstraZeneca, Pierre Fabre, Pfizer, IPSEN; personal fees for copyright transfer from SciClone Pharmaceuticals, IPSEN, Pierre Fabre, MSD, Sanofi Genzyme. Marcello Tiseo: He received honoraria for advisory boards and/or speakers’ fee for AstraZeneca, Pfizer, Eli-Lilly, BMS, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, Pierre Fabre, Amgen and Merck, Sanofi. Research Grants from AstraZeneca and Boehringer Ingelheim. Sebastiano Buti: He received honoraria as a speaker at scientific events and advisory role by BMS, Pfizer, MSD, Ipsen, AstraZeneca and Novartis; he also received research funding from Novartis. The remaining authors have no conflicts of interest to declare.

: The authors affirm that human research participants provided informed consent for publication of individual’s details.

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Area Vasta Emilia Nord protocol (Date September 21, 2021/No37649).

: Informed consent was obtained from all individual participants included in the study.